Spark eyes installment plan for $1M gene therapy; Pharma sales to hit $1.3T by 2018, report says;

> As a pricey gene therapy for blindness nears the market--some expect a cost of $1 million--its maker, Spark Therapeutics, is working with payers on long-term payment options, including pay-for-performance models. Report

> Global pharma sales are projected to grow to $1.3 trillion by 2018, Thomson Reuters says, as more brand-new drugs win approval, particularly in cancer. Report

> Me-too drugs may be due for an image overhaul now that competitive rivalries are helping bring down prices in some areas. Report

> Specialty pharmacy Diplomat ($DPLO) signed up to dispense AstraZeneca's ($AZN) cancer treatment Iressa, which recently won FDA approval for first-line, non-small cell lung cancer treatment. Report

> GlaxoSmithKline ($GSK) rolled out a new Sensodyne campaign in India. Report

> NattoPharma and TG Montgomery partnered up to take the vitamin brand MenaQ7 into Sweden. Report

> Turing Pharmaceuticals bought marketing rights to Daraprim (pyrimethamine) from Impax Laboratories ($IPXL) in a focus on toxoplasmosis and other infectious diseases. Report

And Finally... Roche ($RHHBY) brought in 100 European students for a music and drama festival to explore the intersection of science and music. Release